受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
製品コード:D4010 Batch: D401001
Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.
CAS No. | 1401812-88-1 |
---|---|
Formulation | 1xPBS |
ADC antiody | Lifastuzumab |
ADC cytotoxin | MMAE |
Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
Shipping | Shipped under low temperature conditions |
Purity | 99% |
Protein concentration | 8.79mg/ml |
Endotoxin Level | <1EU/mg |
人間や獣医の診断であるか治療的な使用のためにでない。